The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Long-term administration of oral anti-hepatitis B virus (HBV) nucleoside or nucleotide analogues therapy (NUC) is the first-line treatment option for most patients with chronic hepatitis B infection. Although NUC rapidly inhibits HBV replication in most patients, in the long term, this therapeutic regimen is challenged by the emergence of drug-resistant mutant virions, ultimately leading to treatment...
There are a number of antiviral treatments for chronic hepatitis B currently available, and these include both interferon and a variety of nucleoside and nucleotide analogues. Interferon has been shown in numerous trials to be superior to the nucleoside analogues in inducing virologic, biochemical, histologic, and serologic responses. However, this response is not universal among patients and the...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.